Lotte Biologics Capabilities Update September 2026: ADC

Antibody-drug conjugates (ADCs) and other advanced bioconjugates present unique development and manufacturing challenges that go far beyond conventional monoclonal antibody production. From linker-payload selection and conjugation chemistry to process control, analytical characterization, containment, and scale-up, successful ADC manufacturing requires a highly specialized, science-driven approach.

Attendees will learn how flexible, customer-centric conjugation services can be tailored to meet the specific needs of each molecule and development stage. By combining deep scientific expertise, advanced bioconjugation capabilities, and collaborative program support, we help clients navigate the complexities of ADC development and accelerate the path toward high-quality therapeutic products.